Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder

Cancer Letters

Volumn 245, Issue 1-2, 2007, Pages 121-126

  Christoph, Frank ^a   Weikert, Steffen ^a   Wolff, Ingmar ^a   Schostak, Martin ^a   Tabiti, Karim ^b   Müller, Markus ^a   Miller, Kurt ^a   Schrader, Mark ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Cytokeratin 20; Real time RT PCR; Superficial bladder cancer; Tumor marker

Indexed keywords

CYTOKERATIN 20; MESSENGER RNA;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; CYSTOSCOPY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TRANSITIONAL CELL CARCINOMA; URINARY TRACT DISEASE; UROTHELIUM;

CARCINOMA, TRANSITIONAL CELL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; KERATIN-20; MALE; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 33845654739     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.12.038     Document Type: Article

References (21)

1. F.o.e.c. societies, The ten cancers with highest mortality in 1998, 2005.
2. Jemal A., Thomas A., Murray T., and Thun M. Cancer statistics. 2002. CA Cancer J. Clin. 52 (2002) 23-47
3. Landman J., Chang Y., Kavaler E., Droller M.J., and Liu B.C. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 52 (1998) 398-402
4. Serretta V., Lo Presti D., Vasile P., Gange E., Esposito E., and Menozzi I. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology 52 (1998) 793-796
5. Thomas L., Leyh H., Marberger M., Bombardieri E., Bassi P., Pagano F., et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin. Chem. 45 (1999) 472-477
6. Fradet Y., and Lockhard C. Performance characteristics of a new monoclonal antibody test for bladder cancer: immunoCyt trade mark. Can. J. Urol. 4 (1997) 400-405
7. Jichlinski P., Guillou L., Karlsen S.J., Malmstrom P.U., Jocham D., Brennhovd B., et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study. J. Urol. 170 (2003) 226-229
8. Moll R., Lowe A., Laufer J., and Franke W.W. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am. J. Pathol. 140 (1992) 427-447
9. Harnden P., Eardley I., Joyce A.D., and Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br. J. Urol. 78 (1996) 870-875
10. Klein A., Zemer R., Buchumensky V., Klaper R., and Nissenkorn I. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma. Cancer 82 (1998) 349-354
11. Buchumensky V., Klein A., Zemer R., Kessler O.J., Zimlichman S., and Nissenkorn I. Cytokeratin 20: a new marker for early detection of bladder cell carcinoma?. J. Urol. 160 (1998) 1971-1974
12. Rotem D., Cassel A., Lindenfeld N., Mecz Y., Sova Y., Resnick M., et al. Urinary cytokeratin 20 as a marker for transitional cell carcinoma. Eur. Urol. 37 (2000) 601-604
13. Inoue T., Nakanishi H., Inada K., Hioki T., TatematsuY M., and Sugimura Y. Real time reverse transcriptase polymerase chain reaction of urinary cytokeratin 20 detects transitional cell carcinoma cells. J. Urol. 166 (2001) 2134-2141
14. Alsheikh A., Mohamedali Z., Jones E., Masterson J., and Gilks C.B. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/International Society of Urologic Pathology. Mod. Pathol. 14 (2001) 267-272
15. Desai S., Lim S.D., Jimenez R.E., Chun T., Keane T.E., McKenney J.K., et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod. Pathol. 13 (2000) 1315-1323
16. Ramos D., Navarro S., Villamon R., Gil-Salom M., and Llombart-Bosch A. Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder. Cancer 97 (2003) 1876-1883
17. Golijanin D., Shapiro A., and Pode D. Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer. J. Urol. 164 (2000) 1922-1925
18. Sobin L.H., and Wittekind C. TNM Classification of Malignant Tumours. sixth ed. (2002), Wiley, New York
19. Christoph F., Muller M., Schostak M., Soong R., Tabiti K., and Miller K. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction. Urology 64 (2004) 157-161
20. Okegawa T., Kinjo M., Nutahara K., and Higashihara E. Value of reverse transcription polymerase chain assay in peripheral blood of patients with urothelial cancer. J. Urol. 171 (2004) 1461-1466
21. Lassmann S., Bauer M., Soong R., Schreglmann J., Tabiti K., Nahrig J., et al. Quantification of CK20 gene and protein expression in colorectal cancer by RT-PCR and immunohistochemistry reveals inter- and intratumour heterogeneity. J. Pathol. 198 (2002) 198-206